ATF3:,

Chao He1, Rui Han1,2, Taiming Zhang1,3

  • 1Department of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China.

Thoracic cancer
|April 14, 2025
PubMed
概括

在非小细胞肺癌 (NSCLC) 中确定新辅助化学免疫治疗的受益者至关重要. 新IGS干扰素通路的特征,特别是ATF3基因,准确地预测了对治疗的病理反应.